Opioid Use Disorders
Global death rates from opioid use disorders, country rankings, and trends from 1990 to 2023.
| # | Country | Rate | Region |
|---|
This page presents age-standardized death rates from opioid use disorders across 204 countries and territories, drawing on data from the IHME Global Burden of Disease Study 2024. Opioid Use Disorders mortality patterns vary considerably by geography, income level, and access to healthcare services. Understanding the epidemiology and population-level burden of opioid use disorders is critical for global public health policy, disease prevention strategies, and healthcare resource allocation.
The trend chart above shows how the global opioid use disorders rate has evolved since 1990, reflecting changes in risk factor prevalence, diagnostic capacity, treatment availability, and demographic transitions. Country rankings provide a comparative view of the current burden, highlighting disparities between high-income and low-income nations in opioid use disorders outcomes.
Opioid use disorders involve compulsive use of opioid substances — prescription analgesics such as oxycodone and fentanyl, as well as illicit heroin and increasingly potent synthetic analogues — despite harmful consequences. Death occurs primarily through respiratory depression: opioids bind mu-receptors in the brainstem's respiratory centres, suppressing the drive to breathe, leading to hypoxia, cardiac arrest, and death within minutes of overdose. The opioid crisis has devastated North America, where the United States alone recorded over 80,000 opioid-involved overdose deaths in 2022 — a roughly tenfold increase from 2000. The epidemic evolved in three waves: prescription opioid overprescribing in the late 1990s, a shift to heroin after 2010, and the emergence of illicitly manufactured fentanyl and its analogues after 2013. While North America bears the most visible burden, opioid-related mortality is rising in West Africa (tramadol), the Middle East, and parts of Europe. The social determinants are profound: deindustrialisation, economic despair, adverse childhood experiences, chronic pain mismanagement, and fractured social cohesion all feed the epidemic.
Opioid overdose deaths are preventable through naloxone distribution (the opioid antagonist reverses respiratory depression within minutes), medication-assisted treatment with methadone or buprenorphine, supervised consumption sites, prescription drug monitoring programmes, and evidence-based pain management guidelines that reduce unnecessary opioid prescribing. Harm reduction — including fentanyl test strips and safe supply programmes — addresses the reality that abstinence-only approaches fail many individuals with opioid use disorder.